Current Treatment Options for AMKD and Critical Updates on Clinical Trials: What Tools Do We Have?
b'Guest: Csaba P. Kovesdy, MD
\\n\\n\\n \\n
This program discusses the need to increase awareness about APOL1-Mediated Kidney Disease (AMKD), the clinical impact of genotyping for early diagnosis, disease management, and the need for new small-molecule drug treatments. There is currently a lack of awareness among key decision-makers and in the Black community regarding the health disparities and the importance of genotyping in AMKD. Increasing awareness among nephrologists, hospitalists, geneticists, and patient communities on the impact of early genotyping for APOL1 in Black patients have the potential to improve outcomes and reduce health disparities. Moreover, increasing awareness among nephrologists and patient networks may improve clinical trial participation among underrepresented communities, which can directly impact the development of new AMKD treatments.
'